New PBS listing vital to Australians living with B-cell Acute Lymphoblastic Leukaemia
Thursday, 4 April 2019
The Leukaemia Foundation has welcomed news Australians living with B-cell acute lymphoblastic leukaemia (B-ALL) will have access to the drug inotuzumab ozogamicin (Besponsa®) through the Pharmaceutical Benefits Scheme (PBS) after the listing was announced in this week’s Federal Budget.
According to the Federal Government, Australians living with
New Australian facilities announced for break-through CAR-T therapy and other immunotherapy clinical trials
Tuesday, 26 March 2019
The Leukaemia Foundation welcomes the federal government $80 million investment to establish the Peter MacCallum Centre as a new base for Car-T Cell therapy and other immunotherapy clinical trials in Australia.
The funding package would help to build 2,600 square met facilities to manufacture commercial CAR-T
Leukaemia Foundation to partner with Tour de Cure for the inaugural Life Ride
Tuesday, 26 March 2019
The Leukaemia Foundation and Tour de Cure will combine forces in 2019 to host the first Life Ride – an inspiring three-day cycling event to help fund research and find a cure for blood cancer.
The inaugural Life Ride will be held in the spectacular Margaret River region of Western Australia from Sunday,
Treatment for cutaneous T-cell lymphomas to be subsidised through broadened PBS listing
Thursday, 21 March 2019
The Leukaemia Foundation welcomes the Federal Government’s announcement that the Pharmaceutical Benefits Scheme (PBS) listing of brentuximab vedotin (Adcetris®) will be broadened to include treatment of cutaneous T-cell lymphomas (CTCL) from 1 April 2019.
CTCL is a type of non-Hodgkin lymphoma that directly attacks the body’s T-cells, a type of white
Leukaemia Foundation supports Australian women #BalanceForBetter
Thursday, 07 March 2019
The Leukaemia Foundation is proud to support International Women’s Day, a day to acknowledge and celebrate the social, economic, cultural and political achievements of all women across the globe.
This year, the Leukaemia Foundation is thrilled to recognise two innovative Australian Clinical and Science PhD female investigators, whose work is at the forefront of next generation medical
Hair recycling partnership shaving environment while tackling blood cancer
Friday, 01 March 2019
Social enterprise Sustainable Salons is once again throwing its support behind the Leukaemia Foundation’s World’s Greatest Shave by recycling hundreds of kilograms of hair to be donated for wigs and environmental hair booms thanks to Australia’s brave shavers.
For the second year running, Sustainable Salons are uniting
Breakthrough chronic lymphocytic leukaemia (CLL) treatment now available for Australians
Monday, 25 February 2019
The Leukaemia Foundation welcomes the Federal Government’s announcement that the targeted cancer treatment Venetoclax (Venclexta®), will be added to Pharmaceutical Benefits Scheme (PBS) from 1 March 2019.
Venetoclax will be available in combination with rituximab for patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia
VOLUNTEER RECEIVES OAM FOR 30 YEARS SERVICE TO CHARITIES AND FOUNDATIONS
Wednesday, 30 January 2019
Warwick local and Leukaemia Foundation volunteer, Elaine Stewart was recognised for her vital service and support of Australians living with blood cancer.
Elaine Stewart was awarded an Order of Australia Medal for her selfless work and contribution to the Leukaemia Foundation’s Warwick Branch, as well as her local School’s Chaplaincy Committee and the Riding for the Disabled Association.
A volunteer for more than
Blood cancer patient needs could go unmet as incidence rates rise
Monday, 14 January 2019,
The number of Australians living with a blood cancer is expected to rise around 30 per cent over the next decade, according to new Leukaemia Foundation analysis as it launches World’s Greatest Shave this week.
Currently 12,800 Australians are diagnosed with a blood cancer like leukaemia, lymphoma and myeloma every
Therapeutic Goods Administration (TGA) has today approved the use of the first CAR-T therapy in Australia
Therapeutic Goods Administration (TGA) has today approved the use of the first CAR-T therapy in Australia.
A revolutionary cancer therapy that supercharges a patient’s immune cells to hunt and destroy cancer cells has been approved for use in Australia, ushering in a new era in medicine.
The TGA has